These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10640513)

  • 1. Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants.
    Kohl C; Steinkellner M
    Drug Metab Dispos; 2000 Feb; 28(2):161-8. PubMed ID: 10640513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No clinically relevant effect of lornoxicam intake on acenocoumarol pharmacokinetics and pharmacodynamics.
    Masche UP; Rentsch KM; von Felten A; Meier PJ; Fattinger KE
    Eur J Clin Pharmacol; 1999 Jan; 54(11):865-8. PubMed ID: 10027662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics.
    Masche UP; Rentsch KM; von Felten A; Meier PJ; Fattinger KE
    Eur J Clin Pharmacol; 1999 Jan; 54(11):857-64. PubMed ID: 10027661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
    Ufer M
    Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective interaction between piroxicam and acenocoumarol.
    Bonnabry P; Desmeules J; Rudaz S; Leemann T; Veuthey JL; Dayer P
    Br J Clin Pharmacol; 1996 Jun; 41(6):525-30. PubMed ID: 8799517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.
    Ravic M; Johnston A; Turner P
    Postgrad Med J; 1990; 66 Suppl 4():S30-4. PubMed ID: 2126624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the CYP2C9*3 allele on lornoxicam metabolism.
    Liu YL; Zhang W; Tan ZR; Ouyang DS; Luo CH; Liu ZQ; Qiu Y; Chen Y; He YJ; Zhou G; Zhou HH
    Clin Chim Acta; 2006 Feb; 364(1-2):287-91. PubMed ID: 16182270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam.
    Bonnabry P; Leemann T; Dayer P
    Eur J Clin Pharmacol; 1996; 49(4):305-8. PubMed ID: 8857077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo.
    Ufer M; Kammerer B; Kahlich R; Kirchheiner J; Yasar U; Brockmöller J; Rane A
    Xenobiotica; 2004 Sep; 34(9):847-59. PubMed ID: 15742978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance.
    Takahashi H; Kashima T; Kimura S; Murata N; Takaba T; Iwade K; Abe T; Tainaka H; Yasumori T; Echizen aH
    Drug Metab Dispos; 1999 Oct; 27(10):1179-86. PubMed ID: 10497145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
    Olkkola KT; Brunetto AV; Mattila MJ
    Clin Pharmacokinet; 1994 Feb; 26(2):107-20. PubMed ID: 8162655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation.
    Iida I; Miyata A; Arai M; Hirota M; Akimoto M; Higuchi S; Kobayashi K; Chiba K
    Drug Metab Dispos; 2004 Jan; 32(1):7-9. PubMed ID: 14709614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of lornoxicam. A short half-life oxicam.
    Skjodt NM; Davies NM
    Clin Pharmacokinet; 1998 Jun; 34(6):421-8. PubMed ID: 9646006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes.
    Kammerer B; Kahlich R; Ufer M; Schenkel A; Laufer S; Gleiter CH
    Anal Bioanal Chem; 2005 Nov; 383(6):909-17. PubMed ID: 16237546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon.
    Haustein KO
    Semin Thromb Hemost; 1999; 25(1):5-11. PubMed ID: 10327214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of lornoxicam in man.
    Hitzenberger G; Radhofer-Welte S; Takacs F; Rosenow D
    Postgrad Med J; 1990; 66 Suppl 4():S22-7. PubMed ID: 2284217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
    Sunkara G; Bigler H; Wang Y; Smith H; Prasad P; McLeod J; Ligueros-Saylan M
    Curr Med Res Opin; 2004 Jan; 20(1):41-8. PubMed ID: 14741071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
    He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
    Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Determination of lornoxicam in human plasma by LC/MS/MS].
    Zeng YL; Chen XY; Zhang YF; Zhong DF
    Yao Xue Xue Bao; 2004 Feb; 39(2):132-5. PubMed ID: 15127622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
    Thijssen HH; Flinois JP; Beaune PH
    Drug Metab Dispos; 2000 Nov; 28(11):1284-90. PubMed ID: 11038154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.